We use cookies for a better user experience. Read our Privacy Policy

I Agree

Asthma Treatment Market

Asthma Treatment Market (Treatment Type: Long-term Asthma Control Medications and Quick-relief Medications; and Route of Administration: Inhaled, Oral, Intravenous, and Subcutaneous) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Asthma Treatment Market Outlook 2031

  • The global industry was valued at US$ 24.0 Bn in 2021
  • It is projected to grow at a CAGR of 3.7% from 2022 to 2031 and reach more than US$ 34.5 Bn by the end of 2031

Analysts’ Viewpoint

Increase in awareness about asthma treatment is expected to drive the global asthma treatment market size during the forecast period. Participation of several organizations such as the Centers for Disease Control and Prevention’s National Asthma Control Program to increase awareness about asthma and its treatment is estimated to boost market development. Furthermore, asthma camps conducted by the Asthma Society of India are anticipated to augment the industry during the forecast period.

Rise in prevalence of asthma, increase in adoption of combination therapy, and surge in focus on development of smart/digital inhalers are propelling the demand for asthma treatment. Furthermore, several companies are engaging in collaborations and focusing on product innovation, which is likely to increase the demand for asthma medications. For instance, AstraZeneca partnered with the Avillion Company to develop ‘PT027,’ an asthma rescue inhaler.

Asthma Treatment Market

Asthma Treatment Market Introduction

Asthma is a condition, in which the airways narrow and swell, resulting in extra mucus formation. This can make breathing difficult and cause coughing, a whistling sound, and shortness of breath. Asthma is a minor annoyance for some people. For some, it can be a major issue that disrupts daily activities and could result in a life-threatening asthma attack, which is also called asthma exacerbation.

Symptoms in some people worsen in situations such as exercise-induced asthma, which could be exacerbated by cold and dry air. Irritants in the workplace such as chemical fumes, gases, or dust cause occupational asthma. Airborne allergens such as pollen, mold spores, cockroach waste, or skin and dried saliva shed by pets cause allergy-induced asthma.

Asthma medications include nebulizers and spacers. Nebulizer is preferred for asthma patients. It is a device that can deliver doses of medicines quickly and easily to asthma patients.

Request a sample to get extensive insights into the Asthma Treatment Market

Increase in Disease Burden in Adults and Children Driving Market Progress

Asthma is a major public health issue that affects millions of people across the globe. Genetics or environmental factors, such as microbial exposure, passive smoking, and air pollution, are increasing the disease burden in both adults and children, thereby driving the need for asthma medications.

According to the WHO, asthma affected about 262 million people and 455,000 people succumbed to the disease in 2019. Majority of asthma-related deaths occur in low- and lower-middle-income countries, where underdiagnosis and undertreatment are common.

According to CDC, asthma affects nearly 26 million people in the U.S. The disease is estimated to cost more than US$ 56 Bn annually to the society. Thus, increase in number of asthma patients is projected to drive the demand for treatments for asthma during the forecast period.

Rise in Awareness about Asthma Attack Treatment to Boost Market Statistics

Asthma is one of the common lifelong chronic diseases. People are increasingly becoming aware about asthma and its treatment. World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) to improve awareness about asthma attack treatment across the world. The entire month of May is designated as National Asthma and Allergy Awareness Month to help manage asthma and educate people to raise awareness and improve lives for all. People are aware of common treatment options for asthma such as pressurized metered dose inhalers and dry powder inhalers.

CDC’s National Asthma Control Program aims to support the people in the U.S. in treating asthma in order to achieve better health and improve the quality of life. The program funds states, school programs, and non-government organizations to help them improve their surveillance of asthma, train healthcare professionals, educate individuals and their families about asthma, and explain asthma to the public.

Request a custom report on Asthma Treatment Market

Effective Treatment Augmenting Long-term Asthma Control Medications Segment

In terms of treatment, the global asthma treatment market has been bifurcated into long-term asthma control medications and quick-relief (rescue) medications. The long-term asthma control medications segment dominated the industry in 2021. It is the most effective treatment choice for asthma. Inhaled corticosteroids (ICS) are the most potent and effective long-term asthma medications. GlaxoSmithKline plc's ADVAIR DISKUS and AstraZeneca's Symbicort are vital long-term asthma medications that hold major share in the business.

High Preference for Inhaled Drugs

Based on route of administration, the global market has been classified into inhaled, oral, intravenous, and subcutaneous. The inhaled segment held major share in 2021. Inhaled drug therapy is the most preferred asthma attack treatment, as the drug is directly absorbed into the epithelium of the lung.

Increase in Number of Asthma Therapeutics Dispensed Fueling Retail Pharmacies Segment

In terms of distribution channel, the global asthma treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for the largest share in 2021. This can be ascribed to the increase in number of asthma therapeutics being dispensed through retail pharmacies and rise in the number of retail pharmacies in developing countries.

Regional Analysis of Asthma Treatment Industry

North America accounted for major market share in 2021. This can be ascribed to recent FDA approvals, large number of drugs in pipeline, rise in focus on reducing the number of undiagnosed asthma cases, and availability of early treatment in the region. According to the CDC, in 2017, asthma caused an estimated 1.6 million emergency department (ED) visits and 183,000 hospitalizations in the U.S.

The market in Asia Pacific is expected to expand at a higher CAGR during the forecast period. This can be ascribed to high prevalence of asthma, increase in smoking, and rise in environmental pollution in China and India. According to a study published in the Lung India journal, with an estimated 1.5 crore to 2 crore asthma patients, at least one in every 10 asthma patients globally is from India. Increase in focus on respiratory disease management and rise in awareness about managing asthma are fueling market expansion in the region.

Analysis of Key Players

The global asthma treatment market is consolidated, with the presence of a small number of large companies. Expansion of product portfolio and mergers & acquisitions are the major strategies adopted by the key players. Leading players in the business are Mylan N.V, AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Merck & Co. Inc., Novartis International AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries.

Key Developments

  • In June 2022, Glenmark Pharmaceuticals launched its first fixed-dose combination FDC drug, Indamet, for asthma patients
  • In August 2021, Lupin Pharmaceuticals, one of the renowned pharmaceutical companies, launched its generic drug for asthma in the U.S.
  • In June 2021, Lupin Pharmaceuticals launched a digital asthma educator platform to guide the patients on the correct technique of using inhalers

Leading players have been profiled in the market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.

Global Asthma Treatment Market Snapshot

Attribute

Detail

Size in 2021

US$ 24.0 Bn

Forecast (Value) in 2031

More than US$ 34.5 Bn

Growth Rate

(CAGR)

3.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Treatment Type
    • Long-term Asthma Control Medications
    • Quick-relief (Rescue) Medications
  • Route of Administration
    • Inhaled
    • Oral
    • Intravenous
    • Subcutaneous
  • Distribution Channel
    • Retail Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia & CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Mylan N.V.
  • AstraZeneca plc
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Lupin Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis International AG
  • Sanofi
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries

Customization Scope

Available upon request

Pricing

Available upon request

Asthma Treatment Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global asthma treatment market in 2021?

It was valued at US$ 24.0 Bn in 2021

How big the business is expected to be in 2031?

The industry is projected to reach more than US$ 34.5 Bn by 2031.

What was the CAGR from 2017 to 2021?

The CAGR stood at 3.2% from 2017 to 2021

What is the CAGR projected to be during the forecast period?

The market is anticipated to grow at a CAGR of 3.7% from 2022 to 2031

What are the prominent trends that boost growth?

Increase in adoption of combination therapy and rise in prevalence of asthma

Which region is likely to account for major share during the forecast period?

North America is expected to account for the largest share

Who are the prominent players in the global market?

Mylan N.V, AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Merck & Co. Inc., Novartis International AG, Sanofi, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Asthma Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Asthma Treatment Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

    5.1. Key Industry Events (Mergers & Acquisitions, Treatment Type Launches, Partnerships, etc.)

    5.2. Pipeline Analysis

    5.3. Regulatory Scenario by Region/Globally

    5.4. COVID-19 Pandemic Impact on the Industry

6. Global Asthma Treatment Market Analysis and Forecast, by Treatment Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Treatment Type, 2017–2031

        6.3.1. Long-term Asthma Control Medications

        6.3.2. Quick-relief (Rescue) Medications

    6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Asthma Treatment Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2031

        7.3.1. Inhaled

        7.3.2. Oral

        7.3.3. Intravenous

        7.3.4. Subcutaneous

    7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Asthma Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Retail Pharmacies

        8.3.2. Hospital Pharmacies

        8.3.3. Online Pharmacies

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Asthma Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Asthma Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment Type, 2017–2031

        10.2.1. Long-term Asthma Control Medications

        10.2.2. Quick-relief (Rescue) Medications

    10.3. Market Value Forecast, by Route of Administration, 2017–2031

        10.3.1. Inhaled

        10.3.2. Oral

        10.3.3. Intravenous

        10.3.4. Subcutaneous

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Retail Pharmacies

        10.4.2. Hospital Pharmacies

        10.4.3. Online Pharmacies

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Treatment Type

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Asthma Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment Type, 2017–2031

        11.2.1. Long-term Asthma Control Medications

        11.2.2. Quick-relief (Rescue) Medications

    11.3. Market Value Forecast, by Route of Administration, 2017–2031

        11.3.1. Inhaled

        11.3.2. Oral

        11.3.3. Intravenous

        11.3.4. Subcutaneous

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Retail Pharmacies

        11.4.2. Hospital Pharmacies

        11.4.3. Online Pharmacies

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Treatment Type

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Asthma Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment Type, 2017–2031

        12.2.1. Long-term Asthma Control Medications

        12.2.2. Quick-relief (Rescue) Medications

    12.3. Market Value Forecast, by Route of Administration, 2017–2031

        12.3.1. Inhaled

        12.3.2. Oral

        12.3.3. Intravenous

        12.3.4. Subcutaneous

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Retail Pharmacies

        12.4.2. Hospital Pharmacies

        12.4.3. Online Pharmacies

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Treatment Type

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Asthma Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment Type, 2017–2031

        13.2.1. Long-term Asthma Control Medications

        13.2.2. Quick-relief (Rescue) Medications

    13.3. Market Value Forecast, by Route of Administration, 2017–2031

        13.3.1. Inhaled

        13.3.2. Oral

        13.3.3. Intravenous

        13.3.4. Subcutaneous

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Retail Pharmacies

        13.4.2. Hospital Pharmacies

        13.4.3. Online Pharmacies

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Treatment Type

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Asthma Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Treatment Type, 2017–2031

        14.2.1. Long-term Asthma Control Medications

        14.2.2. Quick-relief (Rescue) Medications

    14.3. Market Value Forecast, by Route of Administration, 2017–2031

        14.3.1. Inhaled

        14.3.2. Oral

        14.3.3. Intravenous

        14.3.4. Subcutaneous

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Retail Pharmacies

        14.4.2. Hospital Pharmacies

        14.4.3. Online Pharmacies

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Treatment Type

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share/Ranking Analysis, by Company (2021)

    15.3. Company Profiles

        15.3.1. Mylan N.V.

            15.3.1.1. Company Overview

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Strategic Overview

        15.3.2. AstraZeneca plc

            15.3.2.1. Company Overview

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Strategic Overview

        15.3.3. Boehringer Ingelheim

            15.3.3.1. Company Overview

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Strategic Overview

        15.3.4. F. Hoffmann-La Roche Ltd.

            15.3.4.1. Company Overview

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Strategic Overview

        15.3.5. GlaxoSmithKline plc.

            15.3.5.1. Company Overview

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Strategic Overview

        15.3.6. Glenmark Pharmaceuticals

            15.3.6.1. Company Overview

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Strategic Overview

        15.3.7. Lupin Pharmaceuticals

            15.3.7.1. Company Overview

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Strategic Overview

        15.3.8. Merck & Co. Inc.

            15.3.8.1. Company Overview

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Strategic Overview

        15.3.9. Novartis International AG

            15.3.9.1. Company Overview

            15.3.9.2. Product Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Strategic Overview

        15.3.10. Sanofi

            15.3.10.1. Company Overview

            15.3.10.2. Product Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Strategic Overview

        15.3.11. Sunovion Pharmaceuticals, Inc.

            15.3.11.1. Company Overview

            15.3.11.2. Product Portfolio

            15.3.11.3. SWOT Analysis

            15.3.11.4. Strategic Overview

        15.3.12. Teva Pharmaceutical Industries

            15.3.12.1. Company Overview

            15.3.12.2. Product Portfolio

            15.3.12.3. SWOT Analysis

            15.3.12.4. Strategic Overview

List of Tables

Table 01: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

Table 02: Global Asthma Treatment Market Value (US$ Bn) Forecast, by 2017‒2031, by Route of Administration

Table 03: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Asthma Treatment Market Value (US$ Bn) Forecast, by Region, 2017–2031

Table 05: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Country, 2017–2031

Table 06: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

Table 07: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

Table 08: North America Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

Table 09: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

Table 11: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

Table 12: Europe Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

Table 13: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

Table 15: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

Table 16: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

Table 17: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

Table 19: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

Table 20: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

Table 21: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Treatment Type, 2017‒2031

Table 23: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Route of Administration, 2017‒2031

Table 24: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, by Distribution Channel, 2017–2031

List of Figures

Figure 01: Global Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

Figure 02: Global Asthma Treatment Market Value Share, by Treatment Type, 2021

Figure 03: Global Asthma Treatment Market Value Share, by Route of Administration, 2021

Figure 04: Global Asthma Treatment Market Value Share, by Distribution Channel, 2021

Figure 05: Global Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 06: Global Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 07: Global Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 08: Global Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 09: Global Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 10: Global Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 11: Global Asthma Treatment Market Value Share Analysis, by Region, 2021 and 2031

Figure 12: Global Asthma Treatment Market Attractiveness Analysis, by Region, 2022–2031

Figure 13: North America Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

Figure 14: North America Asthma Treatment Market Value Share Analysis, by Country, 2021 and 2031

Figure 15: North America Asthma Treatment Market Attractiveness Analysis, by Country, 2022–2031

Figure 16: North America Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 17: North America Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 18: North America Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 19: North America Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 20: North America Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 21: North America Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 22: Europe Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

Figure 23: Europe Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 24: Europe Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 25: Europe Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 26: Europe Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 27: Europe Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 28: Europe Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 29: Europe Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 30: Europe Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 31: Asia Pacific Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

Figure 32: Asia Pacific Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 33: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 34: Asia Pacific Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 35: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 36: Asia Pacific Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 37: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 38: Asia Pacific Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 39: Asia Pacific Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 40: Latin America Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

Figure 41: Latin America Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 42: Latin America Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

Figure 43: Latin America Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 44: Latin America Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 45: Latin America Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 46: Latin America Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 47: Latin America Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 48: Latin America Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 49: Middle East & Africa Asthma Treatment Market Value (US$ Bn) Forecast, 2017–2031

Figure 50: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 51: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031

Figure 52: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Treatment Type, 2021 and 2031

Figure 53: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Treatment Type, 2022–2031

Figure 54: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Route of Administration, 2021 and 2031

Figure 55: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 56: Middle East & Africa Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

Figure 57: Middle East & Africa Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 58: Company Share Analysis, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

199

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved